Skip to content

Early Recurrence Limits Post-recurrence Therapy in Biliary Tract Cancer: A Rationale for Neoadjuvant Chemotherapy.

Oct 2026 · Annals of Surgical Oncology · 1 citation · 15 references
Medicine

TL;DR

Patients with resectable BTC with elevated CA19-9 or clinical lymph node positivity are at high risk of early recurrence and limited treatment feasibility after recurrence, and NAC may improve outcomes in this population by delaying recurrence.

View source

Similar papers

Open access Oct 2026

Risk factors for shorter recurrence-free survival in patients with resected biliary tract cancer treated with adjuvant S-1 chemotherapy.

BACKGROUND Adjuvant S-1 chemotherapy (ASC) has become the standard postoperative treatment for biliary tract cancer (BTC) in Japan following publication of the results of the ASCOT study, a recent nationwide randomized controlled study. However, recurrence remains common, and risk factors specific to patients treated w...

T. Taira, Mitsuhito Sasaki, G. Igarashi et al. · 0 citations
Open access Nov 2026

Impact of Preoperative Chemoradiotherapy on Clinical Outcomes in Elderly Patients With Locally Advanced Rectal Cancer

Preoperative treatment is central to rectal cancer, but its benefit in elderly patients remains unclear. This study evaluated its impact on clinical outcomes in elderly patients undergoing surgery. This cohort included 5,533 patients aged ≥65 years with newly diagnosed locally advanced rectal cancer (LARC) w...

Tung Lin, Te-Min Ke, Wan-Hsuan Chow et al. · 0 citations
Sep 2026

Is postoperative adjuvant therapy necessary for esophageal cancer patients with pathological complete response after neoadjuvant treatment?

BACKGROUND Current National Comprehensive Cancer Network (NCCN) guidelines recommend omission of adjuvant therapy in esophageal cancer patients achieving pathological complete response (pCR) following neoadjuvant treatment. However, 20-40% of these patients experience disease recurrence, potentially indicative of resid...

Zi-An Zhang, Jun-Feng Liu, Jun-Hong Liu et al. · 0 citations
Open access Oct 2026

Post-Recurrence Treatment Patterns and Outcomes After Curative-Intent Multimodality Strategy in Patients with Pleural Mesothelioma: A Retrospective Cohort Study

Background: Disease recurrence is common after surgery for pleural mesothelioma (PM), and the evidence guiding post-recurrence management remains limited. Methods: We conducted a retrospective, single-center cohort study including patients with PM treated within a curative-intent multimodality treatment pathway includi...

O. Illini, H. Fabikan, Irene Berghammer et al. · 0 citations
Open access Oct 2026

Re-evaluating the role of adjuvant chemotherapy after neoadjuvant chemotherapy in resected gastric cancer

Abstract Background Perioperative chemotherapy is the standard of care for resectable gastric cancer (GC), but many patients do not complete adjuvant chemotherapy (AC). It remains unclear whether AC following neoadjuvant chemotherapy (NAC) improves survival. We sought to assess differences in survival between patients...

Aravind Sreeram, Celine Yeh, N. Toumbacaris et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.